“We are evolving from a cottage industry to an industrialized process, part of our challenge is ensuring our data maintains integrity and consistency with that evolution. We need software that can work with our unique Bicycle® platform and take our data quality to the next level. Working with Geneious Biologics to apply this application to the analysis of our unique data sets has been enabling for Bicycle Therapeutics and I can see how this could drastically improve speed and accuracy in other areas of drug development.”
Michael Skynner, Ph.D., Vice President of Operations at Bicycle Therapeutics
Bicycle Therapeutics is developing a new class of medicines to treat oncology and other important diseases based on its proprietary bicyclic peptide (Bicycle®) product platform. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. For more information, visit www.bicycletherapeutics.com
Isogenica licenses advanced synthetic antibody libraries and display technologies to enable its partners’ antibodies discovery activities. These libraries are available for license and screening partnerships, which together with its expertise in the screening of displayed peptide and scaffold libraries, can facilitate client’s biologics discovery needs. Further information at www.isogenica.com.
“Isogenica strives to provide licensees with the best possible synthetic antibody libraries – be it our llamdA™ camelid single domain antibody library or Alexandria™, our fully synthetic conventional human Fab library. Sanger and NGS sequencing play a critical part of the quality control of these Colibra™ built libraries, as well as in validating the results of selection campaigns. The computational power and intuitive interface of Biomatters’ Geneious desktop and now Geneious Biologics have significantly simplified our analyses of these vast datasets.”
Dr. Guy Hermans, CSO at Isogenica Ltd.
“We are processing increasingly larger sets of antibody sequences. Geneious Biologics allows us to drill into huge antibody sequence sets and quickly identify where errors lie and inspect bad clones. This will ensure we return the most effective, stable therapeutic antibody candidates to our clients, faster.”
Daniela Teixeira, COO at FairJourney Biologics
“IONTAS has used the Geneious Biologics platform in the development of bespoke fusion molecules and a novel antibody-like scaffold. Geneious Biologics’ flexibility lets us run detailed analysis on these unique, proprietary therapeutic candidates. The platform has been widely adopted within IONTAS and provides the tools to automate many previously manual and time-consuming aspects of sequence analysis. It has significantly improved the way we do sequence analysis and has facilitated the adoption of Next Generation Sequencing (NGS) methods.”
Aneesh Karatt-Vellatt, Group Leader at IONTAS (KnotBodyTM drug discovery)
“Geneious Biologics will help us scale-up our screening efforts. We are incorporating more high-throughput sequencing into our core business, and are screening increasingly large quantities of unique and complex VHH-based multi-specific biologics. We sought a bioinformatics platform that provides powerful, fast and deep sequence analysis and, importantly, allows us to consolidate and manage our sequence data in a secure environment that can be shared with our partners.”
Bruno Dombrecht, Expert Scientist at VIB Discovery Sciences
VIB is a strategic research center in life sciences and biotech. VIB’s technology transfer team proactively translates new biological findings into new economic activities, such as starting up new companies and partnerships with the biotech and pharmaceutical industry. Since its foundation in 1996, VIB has created 20 start-up companies. More information: www.vib.be.
Often you have to shoehorn a software solution into your process, the adaptability of Geneious Biologics was something we liked a lot. Once we knew what we could do with Geneious Biologics there was no other viable option.
We have been very pleased with the quality of the software, as well as with the interaction with Biomatters’ staff who have proven to be very responsive to technical questions and suggestions for further development.
Companies of our size and nature appreciate working with companies of the same mindset. The advantage with Geneious Biologics is – it is scientists talking to scientists.
One of the remaining bottlenecks to efficiently identify optimal antibody candidates is antibody sequence processing. Providing insight into large antibody sequence and data sets, such as can be retrieved from Isogenica’s fully synthetic human Fab or llamdA VHH domain antibody libraries, will speed up biologic drug development.
Geneious Biologics will allow our licensees to optimally use the data on the large number of leads retrieved from our libraries and, ultimately, enhance biologic drug development processes.
New technologies like Geneious Biologics will play an important role in allowing researchers to better leverage existing molecular data sets.
IONTAS is focused on the development of novel antibody therapeutics. We chose Geneious Biologics as our core software platform for analysis of antibody sequences because of the company’s willingness and ability to meet our specific needs.
IONTAS had a requirement for processing large quantities of data from both our service based antibody discovery projects and our internal developments. The collaboration has been close and resulted in Geneious Biologics delivering a software solution that has significantly improved the efficiency and scope of our sequence analysis workflows during therapeutic antibody discovery.